The complex role of inflammasomes in the pathogenesis of Inflammatory Bowel Diseases - Lessons learned from experimental models

Cytokine and Growth Factor Reviews

Volumn 25, Issue 6, 2014, Pages 715-730

  Aguilera, Mònica ^a   Darby, Trevor ^b   Melgar, Silvia ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Caspase 1; Colitis associated cancer; IBD; Inflammasomes; Microbiota

Indexed keywords

AIM2 PROTEIN; APOPTOSIS ASSOCIATED SPECK LIKE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CELL PROTEIN; CRYOPYRIN; IFI16 PROTEIN; IFIX PROTEIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MNDA PROTEIN; NLRC4 PROTEIN; NLRP1 PROTEIN; NLRP12 PROTEIN; NLRP6 PROTEIN; UNCLASSIFIED DRUG; IL1B PROTEIN, HUMAN; IL1B PROTEIN, MOUSE;

COLITIS; COLON CANCER; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE MODEL; ENZYME ACTIVITY; EXPERIMENTAL MODEL; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MOLECULAR RECOGNITION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; BACTERIUM; GENETICS; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA; MOUSE;

BACTERIA (MICROORGANISMS); MUS;

ANIMALS; BACTERIA; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMASOMES; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-18; INTERLEUKIN-1BETA; MICE; MICROBIOTA;

EID: 84918785361     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.04.003     Document Type: Review

References (164)

1. Dupaul-Chicoine J., Yeretssian G., Doiron K., Bergstrom K.S.B., McIntire C.R., LeBlanc P.M., et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010, 32:367-378.
2. Zaki M.H., Lamkanfi M., Kanneganti T.-D. Inflammasomes and intestinal tumorigenesis. Drug Discov Today Dis Mech 2011, 8:e71-e78.
3. Yeretssian G. Effector functions of NLRs in the intestine: innate sensing, cell death, and disease. Immunol Res 2012, 54:25-36.
4. Becker C.E., O'Neill L.A.J. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin Immunopathol 2007, 29:239-248.
5. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013, 13:397-411.
6. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
7. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
8. Davis B.K., Wen H., Ting J.P.-Y. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011, 29:707-735.
9. Lamkanfi M., Vande Walle L., Kanneganti T.-D. Deregulated inflammasome signaling in disease. Immunol Rev 2011, 243:163-173.
10. Elinav E., Henao-Mejia J., Flavell R.A. Integrative inflammasome activity in the regulation of intestinal mucosal immune responses. Mucosal Immunol 2013, 6:4-13.
11. Rathinam V.a.K., Vanaja S.K., Fitzgerald Ka. Regulation of inflammasome signaling. Nat Immunol 2012, 13:333-342.
12. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518.
13. Unterholzner L., Keating S.E., Baran M., Horan K.A., Jensen S.B., Sharma S., et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010, 11:997-1004.
14. Jin T., Perry A., Jiang J., Smith P., Curry J.A., Unterholzner L., et al. Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity 2012, 36:561-571.
15. Kang T.-B., Yang S.-H., Toth B., Kovalenko A., Wallach D. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 2013, 38:27-40.
16. Man S.M., Tourlomousis P., Hopkins L., Monie T.P., Fitzgerald K.A., Bryant C.E. Salmonella infection induces recruitment of Caspase-8 to the inflammasome to modulate IL-1β production. J Immunol 2013, 191:5239-5246.
17. Jha S., Ting J.P.-Y. Inflammasome-associated nucleotide-binding domain, leucine-rich repeat proteins and inflammatory diseases. J Immunol 2009, 183:7623-7629.
18. Coccia M., Harrison O.J., Schiering C., Asquith M.J., Becher B., Powrie F., et al. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med 2012, 209:1595-1609.
19. Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008, 223:20-38.
20. Lefrançais E, Cayrol C. Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur Cytokine Netw n.d.;23:120-7.
21. DeYoung K.L., Ray M.E., Su Y.A., Anzick S.L., Johnstone R.W., Trapani J.A., et al. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene 1997, 15:453-457.
22. Bürckstümmer T., Baumann C., Blüml S., Dixit E., Dürnberger G., Jahn H., et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009, 10:266-272.
23. Miao E.A., Warren S.E. Innate immune detection of bacterial virulence factors via the NLRC4 inflammasome. J Clin Immunol 2010, 30:502-506.
24. Carvalho F.A., Nalbantoglu I., Aitken J.D., Uchiyama R., Su Y., Doho G.H., et al. Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges. Mucosal Immunol 2012, 5:288-298.
25. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet 2012, 380:1590-1605.
26. Melgar S., Shanahan F. Inflammatory bowel disease-from mechanisms to treatment strategies. Autoimmunity 2010, 43:463-477.
27. Ordás I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative colitis. Lancet 2012, 380:1606-1619.
28. Mahida Y.R., Wu K., Jewell D.P. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989, 30:835-838.
29. Pizarro T.T., Michie M.H., Bentz M., Woraratanadharm J., Smith M.F., Foley E., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999, 162:6829-6835.
30. McAlindon M.E., Hawkey C.J., Mahida Y.R. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 1998, 42:214-219.
31. Monteleone G., Trapasso F., Parrello T., Biancone L., Stella A., Iuliano R., et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999, 163:143-147.
32. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
33. Taniguchi S., Sagara J. Regulatory molecules involved in inflammasome formation with special reference to a key mediator protein, ASC. Semin Immunopathol 2007, 29:231-238.
34. Feng Q., Li P., Leung P.C.K., Auersperg N. Caspase-1zeta, a new splice variant of the caspase-1 gene. Genomics 2004, 84:587-591.
35. Siegmund B., Lehr H.A., Fantuzzi G., Dinarello C.A. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 2001, 98:13249-13254.
36. Bersudsky M., Luski L., Fishman D., White R.M., Ziv-Sokolovskaya N., Dotan S., et al. Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice. Gut 2014, 63:598-609.
37. Loher F., Bauer C., Landauer N., Schmall K., Siegmund B., Lehr H.A., et al. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 2004, 308:583-590.
38. Liu J.J., Davis E.M., Wine E., Lou Y., Rudzinski J.K., Alipour M., et al. Epithelial cell extrusion leads to breaches in the intestinal epithelium. Inflamm Bowel Dis 2013, 19:912-921.
39. Zaki M.H., Vogel P., Body-Malapel M., Lamkanfi M., Kanneganti T.-D. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol 2010, 185:4912-4920.
40. Hu B., Elinav E., Huber S., Strowig T., Hao L., Hafemann A., et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc Natl Acad Sci U S A 2013, 110:9862-9867.
41. Mariathasan S., Newton K., Monack D.M., Vucic D., French D.M., Lee W.P., et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004, 430:213-218.
42. Stehlik C., Fiorentino L., Dorfleutner A., Bruey J.-M., Ariza E.M., Sagara J., et al. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J Exp Med 2002, 196:1605-1615.
43. Elinav E., Strowig T., Kau A.L., Henao-Mejia J., Thaiss C.A., Booth C.J., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-757.
44. Sussman D.A., Santaolalla R., Strobel S., Dheer R., Abreu M.T. Cancer in inflammatory bowel disease: lessons from animal models. Curr Opin Gastroenterol 2012, 28:327-333.
45. Ludwiczek O., Vannier E., Borggraefe I., Kaser A., Siegmund B., Dinarello C.A., et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004, 138:323-329.
46. Casini-Raggi V., Kam L., Chong Y.J., Fiocchi C., Pizarro T.T., Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995, 154:2434-2440.
47. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702.
48. Melgar S., Karlsson A., Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005, 288:G1328-G1338.
49. Carter J.D., Valeriano J., Vasey F.B. Crohn disease worsened by anakinra administration. J Clin Rheumatol 2003, 9:276-277.
50. Shi J., Aono S., Lu W., Ouellette A.J., Hu X., Ji Y., et al. A novel role for defensins in intestinal homeostasis: regulation of IL-1beta secretion. J Immunol 2007, 179:1245-1253.
51. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
52. Sahoo M., Ceballos-Olvera I., del Barrio L., Re F. Role of the inflammasome, IL-1β, and IL-18 in bacterial infections. Sci World J 2011, 11:2037-2050.
53. Siegmund B., Fantuzzi G., Rieder F., Gamboni-Robertson F., Lehr H.A., Hartmann G., et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1264-R1273.
54. Sivakumar P.V., Westrich G.M., Kanaly S., Garka K., Born T.L., Derry J.M.J., et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002, 50:812-820.
55. Siegmund B. Interleukin-18 in intestinal inflammation: friend and foe?. Immunity 2010, 32:300-302.
56. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007, 59:1073-1083.
57. Lopetuso L.R., Chowdhry S., Pizarro T.T. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol 2013, 4:181.
58. Allen I.C., TeKippe E.M., Woodford R.-M.T., Uronis J.M., Holl E.K., Rogers A.B., et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010, 207:1045-1056.
59. Rodrigue-Gervais I.G., Saleh M. Genetics of inflammasome-associated disorders: a lesson in the guiding principals of inflammasome function. Eur J Immunol 2010, 40:643-648.
60. Lees C.W., Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol 2009, 3:513-534.
61. Ventham N.T., Kennedy N.A., Nimmo E.R., Satsangi J. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013, 145:293-308.
62. Villani A.-C., Franchimont D. The contribution of genetic studies in shifting the immunopathogenesis paradigm of Crohn's disease. Expert Rev Clin Immunol 2009, 5:361-364.
63. Sahoo B.R., Swain B., Dikhit M.R., Basu M., Bej A., Jayasankar P., et al. Activation of nucleotide-binding oligomerization domain 1 (NOD1) receptor signaling in Labeo rohita by iE-DAP and identification of ligand-binding key motifs in NOD1 by molecular modeling and docking. Appl Biochem Biotechnol 2013, 170:1282-1309.
64. Cummings J.R.F., Cooney R.M., Clarke G., Beckly J., Geremia A., Pathan S., et al. The genetics of NOD-like receptors in Crohn's disease. Tissue Antigens 2010, 76:48-56.
65. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009, 27:621-668.
66. Schoultz I., Verma D., Halfvarsson J., Törkvist L., Fredrikson M., Sjöqvist U., et al. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am J Gastroenterol 2009, 104:1180-1188.
67. Villani A.-C., Lemire M., Fortin G., Louis E., Silverberg M.S., Collette C., et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009, 41:71-76.
68. Lewis G.J., Massey D.C.O., Zhang H., Bredin F., Tremelling M., Lee J.C., et al. Genetic association between NLRP3 variants and Crohn's disease does not replicate in a large UK panel. Inflamm Bowel Dis 2011, 17:1387-1391.
69. Hampe J., Franke A., Rosenstiel P., Till A., Teuber M., Huse K., et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007, 39:207-211.
70. Travassos L.H., Carneiro L.a.M., Ramjeet M., Hussey S., Kim Y.-G., Magalhães J.G., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010, 11:55-62.
71. Lu C., Chen J., Xu H.-G., Zhou X., He Q., Li Y.-L., et al. MIR106B and MIR93 prevent removal of bacteria from epithelial cells by disrupting ATG16L1-mediated autophagy. Gastroenterology 2014, 146:188-199.
72. Saitoh T., Fujita N., Jang M.H., Uematsu S., Yang B.-G., Satoh T., et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008, 456:264-268.
73. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
74. Nakahira K., Haspel J.A., Rathinam V.A.K., Lee S.-J., Dolinay T., Lam H.C., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011, 12:222-230.
75. Bauernfeind F., Ablasser A., Bartok E., Kim S., Schmid-Burgk J., Cavlar T., et al. Inflammasomes: current understanding and open questions. Cell Mol Life Sci 2011, 68:765-783.
76. Boyden E.D., Dietrich W.F. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 2006, 38:240-244.
77. Wen H., Miao E.A., Ting J.P.-Y. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 2013, 39:432-441.
78. Bryant C., Fitzgerald K.A. Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 2009, 19:455-464.
79. Hanamsagar R., Hanke M.L., Kielian T. Toll-like receptor (TLR) and inflammasome actions in the central nervous system. Trends Immunol 2012, 33:333-342.
80. Kummer J.A., Broekhuizen R., Everett H., Agostini L., Kuijk L., Martinon F., et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem 2007, 55:443-452.
81. Lech M., Avila-Ferrufino A., Skuginna V., Susanti H.E., Anders H.-J. Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int Immunol 2010, 22:717-728.
82. Chen G.Y., Núñez G. Inflammasomes in intestinal inflammation and cancer. Gastroenterology 2011, 141:1986-1999.
83. Chen G.Y., Shaw M.H., Redondo G., Núñez G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 2008, 68:10060-10067.
84. Slavova N., Drescher A., Visekruna A., Dullat S., Kroesen A.J., Ritz J.-P., et al. NALP expression in Paneth cells provides a novel track in IBD signaling. Langenbecks Arch Surg 2010, 395:351-357.
85. Hedl M., Abraham C. NLRP1 and NLRP3 inflammasomes are essential for distinct outcomes of decreased cytokines but enhanced bacterial killing upon chronic Nod2 stimulation. Am J Physiol Gastrointest Liver Physiol 2013, 304:G583-G596.
86. Watanabe T., Asano N., Murray P.J., Ozato K., Tailor P., Fuss I.J., et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008, 118:545-559.
87. Allen I.C., Scull M.A., Moore C.B., Holl E.K., McElvania-TeKippe E., Taxman D.J., et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009, 30:556-565.
88. Hise A.G., Tomalka J., Ganesan S., Patel K., Hall B.A., Brown G.D., et al. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 2009, 5:487-497.
89. Muñoz-Planillo R., Franchi L., Miller L.S., Núñez G. A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J Immunol 2009, 183:3942-3948.
90. Kim S., Bauernfeind F., Ablasser A., Hartmann G., Fitzgerald K.A., Latz E., et al. Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur J Immunol 2010, 40:1545-1551.
91. Mariathasan S., Weiss D.S., Newton K., McBride J., O'Rourke K., Roose-Girma M., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440:228-232.
92. Pétrilli V., Papin S., Dostert C., Mayor A., Martinon F., Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007, 14:1583-1589.
93. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9:847-856.
94. López-Castejón G., Pelegrín P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs 2012, 21:995-1007.
95. Cario E. Heads up! How the intestinal epithelium safeguards mucosal barrier immunity through the inflammasome and beyond. Curr Opin Gastroenterol 2010, 26:583-590.
96. Franchi L., Eigenbrod T., Núñez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 2009, 183:792-796.
97. Harder J., Franchi L., Muñoz-Planillo R., Park J.-H., Reimer T., Núñez G. Activation of the Nlrp3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-kappa B activation but proceeds independently of TLR signaling and P2X7 receptor. J Immunol 2009, 183:5823-5829.
98. Lamkanfi M., Mueller J.L., Vitari A.C., Misaghi S., Fedorova A., Deshayes K., et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009, 187:61-70.
99. Kayagaki N., Warming S., Lamkanfi M., Vande Walle L., Louie S., Dong J., et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011, 479:117-121.
100. Viganò E., Mortellaro A. Caspase-11: the driving factor for noncanonical inflammasomes. Eur J Immunol 2013, 43:2240-2245.
101. Kayagaki N., Wong M.T., Stowe I.B., Ramani S.R., Gonzalez L.C., Akashi-Takamura S., et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 2013, 341:1246-1249.
102. Harris J., Hartman M., Roche C., Zeng S.G., O'Shea A., Sharp F.A., et al. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem 2011, 286:9587-9597.
103. De la Fuente M., Franchi L., Araya D., Díaz-Jiménez D., Olivares M., Alvarez-Lobos M., et al. Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome. Int J Med Microbiol 2014.
104. Bauer C., Duewell P., Lehr H.-A., Endres S., Schnurr M. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis 2012, 30(Suppl. 1):82-90.
105. Liu W., Guo W., Wu J., Luo Q., Tao F., Gu Y., et al. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol 2013, 85:1504-1512.
106. Bauer C., Duewell P., Mayer C., Lehr H.A., Fitzgerald K.a., Dauer M., et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010, 59:1192-1199.
107. Zhang J., Fu S., Sun S., Li Z., Guo B. Inflammasome activation has an important role in the development of spontaneous colitis. Mucosal Immunol 2014.
108. Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.-D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32:379-391.
109. Elinav E., Strowig T., Henao-Mejia J., Flavell Ra. Regulation of the antimicrobial response by NLR proteins. Immunity 2011, 34:665-679.
110. Hirota S.A., Ng J., Lueng A., Khajah M., Parhar K., Li Y., et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2011, 17:1359-1372.
111. Elinav E., Thaiss C.A., Flavell R.A. Analysis of microbiota alterations in inflammasome-deficient mice. Methods Mol Biol 2013, 1040:185-194.
112. Chen G.Y., Liu M., Wang F., Bertin J., Núñez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 2011, 186:7187-7194.
113. Normand S., Delanoye-Crespin A., Bressenot A., Huot L., Grandjean T., Peyrin-Biroulet L., et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A 2011, 108:9601-9606.
114. Elinav E., Nowarski R., Thaiss C.A., Hu B., Jin C., Flavell R.A. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013, 13:759-771.
115. Sun Y., Zhang M., Chen C.-C., Gillilland M., Sun X., El-Zaatari M., et al. Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 2013, 144:1478-1487. 1487.e1-8.
116. Dubuquoy L., Jansson E.A., Deeb S., Rakotobe S., Karoui M., Colombel J.-F., et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003, 124:1265-1276.
117. Lewis J.D., Lichtenstein G.R., Stein R.B., Deren J.J., Judge T.A., Fogt F., et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001, 96:3323-3328.
118. Pedersen G., Brynskov J. Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. Am J Gastroenterol 2010, 105:1595-1603.
119. Celinski K., Dworzanski T., Fornal R., Korolczuk A., Madro A., Slomka M. Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis. J Physiol Pharmacol 2012, 63:631-640.
120. Lich J.D., Williams K.L., Moore C.B., Arthur J.C., Davis B.K., Taxman D.J., et al. Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. J Immunol 2007, 178:1256-1260.
121. Pinheiro A.S., Eibl C., Ekman-Vural Z., Schwarzenbacher R., Peti W. The NLRP12 pyrin domain: structure, dynamics, and functional insights. J Mol Biol 2011, 413:790-803.
122. Ye Z., Lich J.D., Moore C.B., Duncan J.A., Williams K.L., Ting J.P.-Y. ATP binding by monarch-1/NLRP12 is critical for its inhibitory function. Mol Cell Biol 2008, 28:1841-1850.
123. Williams K.L., Lich J.D., Duncan J.A., Reed W., Rallabhandi P., Moore C., et al. The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J Biol Chem 2005, 280:39914-39924.
124. Arthur J.C., Lich J.D., Ye Z., Allen I.C., Gris D., Wilson J.E., et al. Cutting edge: NLRP12 controls dendritic and myeloid cell migration to affect contact hypersensitivity. J Immunol 2010, 185:4515-4519.
125. Zhong Y., Kinio A., Saleh M. Functions of NOD-like receptors in human diseases. Front Immunol 2013, 4:333.
126. Zaki M.H., Vogel P., Malireddi R.K.S., Body-Malapel M., Anand P.K., Bertin J., et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011, 20:649-660.
127. Allen I.C., Wilson J.E., Schneider M., Lich J.D., Roberts Ra, Arthur J.C., et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity 2012, 36:742-754.
128. Qu Y., Misaghi S., Izrael-Tomasevic A., Newton K., Gilmour L.L., Lamkanfi M., et al. Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 2012, 490:539-542.
129. Kofoed E.M., Vance R.E. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011, 477:592-595.
130. Endrizzi M.G., Hadinoto V., Growney J.D., Miller W., Dietrich W.F. Genomic sequence analysis of the mouse Naip gene array. Genome Res 2000, 10:1095-1102.
131. Vinzing M., Eitel J., Lippmann J., Hocke A.C., Zahlten J., Slevogt H., et al. NAIP and Ipaf control Legionella pneumophila replication in human cells. J Immunol 2008, 180:6808-6815.
132. Sadasivam S., Gupta S., Radha V., Batta K., Kundu T.K., Swarup G. Caspase-1 activator Ipaf is a p53-inducible gene involved in apoptosis. Oncogene 2005, 24:627-636.
133. Franchi L., Kamada N., Nakamura Y., Burberry A., Kuffa P., Suzuki S., et al. NLRC4-driven production of IL-1β discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol 2012, 13:449-456.
134. Fernandes-Alnemri T., Yu J.-W., Juliana C., Solorzano L., Kang S., Wu J., et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 2010, 11:385-393.
135. Liu Z., Zaki M.H., Vogel P., Gurung P., Finlay B.B., Deng W., et al. Role of inflammasomes in host defense against Citrobacter rodentium infection. J Biol Chem 2012, 287:16955-16964.
136. Rathinam V.A.K., Jiang Z., Waggoner S.N., Sharma S., Cole L.E., Waggoner L., et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010, 11:395-402.
137. Jones J.W., Kayagaki N., Broz P., Henry T., Newton K., O'Rourke K., et al. Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc Natl Acad Sci U S A 2010, 107:9771-9776.
138. Rehman A., Sina C., Gavrilova O., Häsler R., Ott S., Baines J.F., et al. Nod2 is essential for temporal development of intestinal microbial communities. Gut 2011, 60:1354-1362.
139. Anand P.K., Malireddi R.K.S., Lukens J.R., Vogel P., Bertin J., Lamkanfi M., et al. NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens. Nature 2012, 488:389-393.
140. Hu B., Elinav E., Flavell R.A. Inflammasome-mediated suppression of inflammation-induced colorectal cancer progression is mediated by direct regulation of epithelial cell proliferation. Cell Cycle 2011, 10:1936-1939.
141. Hu B., Elinav E., Huber S., Booth C.J., Strowig T., Jin C., et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 2010, 107:21635-21640.
142. Arthur J.C., Perez-Chanona E., Mühlbauer M., Tomkovich S., Uronis J.M., Fan T.-J., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
143. Zackular J.P., Baxter N.T., Iverson K.D., Sadler W.D., Petrosino J.F., Chen G.Y., et al. The gut microbiome modulates colon tumorigenesis. MBio 2013, 4:e00692-e713.
144. Song X., Gao H., Lin Y., Yao Y., Zhu S., Wang J., et al. Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. Immunity 2014, 40:140-152.
145. Candela M., Turroni S., Biagi E., Carbonero F., Rampelli S., Fiorentini C., et al. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol 2014, 20:908-922.
146. Ayres J.S., Trinidad N.J., Vance R.E. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med 2012, 18:799-806.
147. Lamkanfi M., Dixit V.M. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 2012, 28:137-161.
148. Huang E.Y., Devkota S., Moscoso D., Chang E.B., Leone V.A. The role of diet in triggering human inflammatory disorders in the modern age. Microbes Infect 2013, 15:765-774.
149. He Y., Franchi L., Núñez G. The protein kinase PKR is critical for LPS-induced iNOS production but dispensable for inflammasome activation in macrophages. Eur J Immunol 2013, 43:1147-1152.
150. Khare S., Dorfleutner A., Bryan N.B., Yun C., Radian A.D., de Almeida L., et al. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity 2012, 36:464-476.
151. Vladimer G.I., Weng D., Paquette S.W.M., Vanaja S.K., Rathinam V.A.K., Aune M.H., et al. The NLRP12 inflammasome recognizes Yersinia pestis. Immunity 2012, 37:96-107.
152. Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbäck P., et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012, 488:670-674.
153. Landin Malt A., Georges A., Silber J., Zider A., Flagiello D. Interaction with the Yes-associated protein (YAP) allows TEAD1 to positively regulate NAIP expression. FEBS Lett 2013, 587:3216-3223.
154. Haque A., Koide N., Odkhuu E., Tsolmongyn B., Naiki Y., Komatsu T., et al. Mouse pyrin and HIN domain family member 1 (pyhin1) protein positively regulates LPS-induced IFN-β and NO production in macrophages. Innate Immun 2014, 20:40-48.
155. Masumoto J., Taniguchi S., Sagara J. Pyrin N-terminal homology domain- and caspase recruitment domain-dependent oligomerization of ASC. Biochem Biophys Res Commun 2001, 280:652-655.
156. Masumoto J., Taniguchi S., Ayukawa K., Sarvotham H., Kishino T., Niikawa N., et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chem 1999, 274:33835-33838.
157. LeBlanc P.M., Yeretssian G., Rutherford N., Doiron K., Nadiri A., Zhu L., et al. Caspase-12 modulates NOD signaling and regulates antimicrobial peptide production and mucosal immunity. Cell Host Microbe 2008, 3:146-157.
158. Arai Y., Takanashi H., Kitagawa H., Okayasu I. Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice. Cytokine 1998, 10:890-896.
159. Roberts R.L., Topless R.K.G., Phipps-Green A.J., Gearry R.B., Barclay M.L., Merriman T.R. Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes Immun 2010, 11:351-356.
160. Ferreira A.C., Almeida S., Tavares M., Canedo P., Pereira F., Regalo G., et al. NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn's disease. Inflamm Bowel Dis 2005, 11:331-339.
161. Andersen V., Ernst A., Christensen J., Østergaard M., Jacobsen B.A., Tjønneland A., et al. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Med Genet 2010, 11:82.
162. Tamura K., Fukuda Y., Sashio H., Takeda N., Bamba H., Kosaka T., et al. IL18 polymorphism is associated with an increased risk of Crohn's disease. J Gastroenterol 2002, 37(Suppl. 1):111-116.
163. Takagawa T., Tamura K., Takeda N., Tomita T., Ohda Y., Fukunaga K., et al. Association between IL-18 gene promoter polymorphisms and inflammatory bowel disease in a Japanese population. Inflamm Bowel Dis 2005, 11:1038-1043.
164. Zhernakova A., Festen E.M., Franke L., Trynka G., van Diemen C.C., Monsuur A.J., et al. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet 2008, 82:1202-1210.